Ascendis Pharma stock rating reiterated by Cantor Fitzgerald ahead of Q2 results

Ascendis Pharma (ASND) is attracting strong analyst confidence ahead of its Q2 earnings report, with Cantor Fitzgerald reiterating an Overweight rating and $200 price target, projecting Yorvipath U.S. sales to exceed $93 million, well above the $83 million Wall Street consensus. This bullish outlook, echoed by Morgan Stanley and UBS, is bolstered by recent FDA approval for SKYTROFA in adults and positive three-year Phase 3 data for Yorvipath, contributing to the stock's 43% surge over the past six months and its proximity to a 52-week high.

Analysis

Analyst sentiment for Ascendis Pharma (ASND) is strongly bullish heading into its second-quarter earnings report, centered on high expectations for its hypoparathyroidism treatment, Yorvipath. Cantor Fitzgerald reiterated an Overweight rating and a $200 price target, forecasting Yorvipath U.S. sales will surpass $93 million, a figure significantly above the Wall Street consensus of $83 million, which the firm deems "very conservative." This sales figure is presented as a critical threshold required to drive the stock higher, based on Cantor's buyside survey. The positive outlook is reinforced by recent coverage initiation from Morgan Stanley at Overweight and a reiterated Buy rating from UBS, both citing the drug's strong launch and commercial potential. This confidence is further supported by solidifying fundamentals, including the recent FDA approval for SKYTROFA in adults, which expands its addressable market, and positive three-year Phase 3 trial data for Yorvipath, confirming its sustained benefits. With the stock having already appreciated 43% in the past six months and trading near its 52-week high, market expectations are demonstrably elevated.

Key Decisions for Investors

• Investors should focus on the upcoming Q2 earnings report, where the key metric will be Yorvipath sales figures relative to the elevated $93 million forecast from Cantor Fitzgerald, not just the $83 million Wall Street consensus.
• Given the stock's 43% run-up and strong bullish consensus, a significant amount of positive news is likely priced in, creating a risk of a 'sell-the-news' reaction if earnings do not substantially beat high expectations.
• Long-term investors may consider the expanding drug portfolio, including the recent SKYTROFA approval and positive long-term Yorvipath data, as fundamental strengths that could support the thesis beyond short-term earnings volatility.